GRAIL is trading 5.17% higher at $139.47 on October 9, 2026, with no clear company-specific event identified to explain the move. - In pre-market, GRAIL was reported at $144.12, up 8.68%. - FDA staff reportedly raised no major concerns ahead of Wednesday’s advisory panel review. Shares had surged earlier in the week on that news, but reporting does not link it to the October 9 move. - The biotech sector is down, which does not explain GRAIL’s gain.